Identification and management of poor response to growth-promoting therapy in children with short stature

Peter Bang, S. Faisal Ahmed, Jesús Argente, Philippe Backeljauw, Markus Bettendorf, Gianni Bona, Régis Coutant, Ronald (Ron) Rosenfeld, Marie José Walenkamp, Martin O. Savage

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Growth hormone (GH) is widely prescribed for children with short stature across a range of growth disorders. Recombinant human (rh) insulin-like growth factor-1 (rhIGF-1) therapy is approved for severe primary IGF-I deficiency - a state of severe GH resistance. Evidence is increasing for an unacceptably high rate of poor or unsatisfactory response to growth-promoting therapy (i.e. not leading to significant catch up growth) in terms of change in height standard deviation score (SDS) and height velocity (HV) in many approved indications. Consequently, there is a need to define poor response and to prevent or correct it by optimizing treatment regimens within accepted guidelines. Recognition of a poor response is an indication for action by the treating physician, either to modify the therapy or to review the primary diagnosis leading either to discontinuation or change of therapy. This review discusses the optimal investigation of the child who is a candidate for GH or IGF-1 therapy so that a diagnosis-based choice of therapy and dosage can be made. The relevant parameters in the evaluation of growth response are described together with the definitions of poor response. Prevention of poor response is addressed by discussion of strategy for first-year management with GH and IGF-1. Adherence to therapy is reviewed as is the recommended action following the identification of the poorly responding patient. The awareness, recognition and management of poor response to growth-promoting therapy will lead to better patient care, greater cost-effectiveness and increased opportunities for clinical benefit.

Original languageEnglish (US)
Pages (from-to)169-181
Number of pages13
JournalClinical Endocrinology
Volume77
Issue number2
DOIs
StatePublished - Aug 2012

Fingerprint

Growth
Growth Hormone
Insulin-Like Growth Factor I
Therapeutics
Growth Disorders
Somatomedins
Cost-Benefit Analysis
Patient Care
Guidelines
Physicians

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Bang, P., Faisal Ahmed, S., Argente, J., Backeljauw, P., Bettendorf, M., Bona, G., ... Savage, M. O. (2012). Identification and management of poor response to growth-promoting therapy in children with short stature. Clinical Endocrinology, 77(2), 169-181. https://doi.org/10.1111/j.1365-2265.2012.04420.x

Identification and management of poor response to growth-promoting therapy in children with short stature. / Bang, Peter; Faisal Ahmed, S.; Argente, Jesús; Backeljauw, Philippe; Bettendorf, Markus; Bona, Gianni; Coutant, Régis; Rosenfeld, Ronald (Ron); Walenkamp, Marie José; Savage, Martin O.

In: Clinical Endocrinology, Vol. 77, No. 2, 08.2012, p. 169-181.

Research output: Contribution to journalArticle

Bang, P, Faisal Ahmed, S, Argente, J, Backeljauw, P, Bettendorf, M, Bona, G, Coutant, R, Rosenfeld, RR, Walenkamp, MJ & Savage, MO 2012, 'Identification and management of poor response to growth-promoting therapy in children with short stature', Clinical Endocrinology, vol. 77, no. 2, pp. 169-181. https://doi.org/10.1111/j.1365-2265.2012.04420.x
Bang, Peter ; Faisal Ahmed, S. ; Argente, Jesús ; Backeljauw, Philippe ; Bettendorf, Markus ; Bona, Gianni ; Coutant, Régis ; Rosenfeld, Ronald (Ron) ; Walenkamp, Marie José ; Savage, Martin O. / Identification and management of poor response to growth-promoting therapy in children with short stature. In: Clinical Endocrinology. 2012 ; Vol. 77, No. 2. pp. 169-181.
@article{16f60745c4b543829e5287e20d174929,
title = "Identification and management of poor response to growth-promoting therapy in children with short stature",
abstract = "Growth hormone (GH) is widely prescribed for children with short stature across a range of growth disorders. Recombinant human (rh) insulin-like growth factor-1 (rhIGF-1) therapy is approved for severe primary IGF-I deficiency - a state of severe GH resistance. Evidence is increasing for an unacceptably high rate of poor or unsatisfactory response to growth-promoting therapy (i.e. not leading to significant catch up growth) in terms of change in height standard deviation score (SDS) and height velocity (HV) in many approved indications. Consequently, there is a need to define poor response and to prevent or correct it by optimizing treatment regimens within accepted guidelines. Recognition of a poor response is an indication for action by the treating physician, either to modify the therapy or to review the primary diagnosis leading either to discontinuation or change of therapy. This review discusses the optimal investigation of the child who is a candidate for GH or IGF-1 therapy so that a diagnosis-based choice of therapy and dosage can be made. The relevant parameters in the evaluation of growth response are described together with the definitions of poor response. Prevention of poor response is addressed by discussion of strategy for first-year management with GH and IGF-1. Adherence to therapy is reviewed as is the recommended action following the identification of the poorly responding patient. The awareness, recognition and management of poor response to growth-promoting therapy will lead to better patient care, greater cost-effectiveness and increased opportunities for clinical benefit.",
author = "Peter Bang and {Faisal Ahmed}, S. and Jes{\'u}s Argente and Philippe Backeljauw and Markus Bettendorf and Gianni Bona and R{\'e}gis Coutant and Rosenfeld, {Ronald (Ron)} and Walenkamp, {Marie Jos{\'e}} and Savage, {Martin O.}",
year = "2012",
month = "8",
doi = "10.1111/j.1365-2265.2012.04420.x",
language = "English (US)",
volume = "77",
pages = "169--181",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Identification and management of poor response to growth-promoting therapy in children with short stature

AU - Bang, Peter

AU - Faisal Ahmed, S.

AU - Argente, Jesús

AU - Backeljauw, Philippe

AU - Bettendorf, Markus

AU - Bona, Gianni

AU - Coutant, Régis

AU - Rosenfeld, Ronald (Ron)

AU - Walenkamp, Marie José

AU - Savage, Martin O.

PY - 2012/8

Y1 - 2012/8

N2 - Growth hormone (GH) is widely prescribed for children with short stature across a range of growth disorders. Recombinant human (rh) insulin-like growth factor-1 (rhIGF-1) therapy is approved for severe primary IGF-I deficiency - a state of severe GH resistance. Evidence is increasing for an unacceptably high rate of poor or unsatisfactory response to growth-promoting therapy (i.e. not leading to significant catch up growth) in terms of change in height standard deviation score (SDS) and height velocity (HV) in many approved indications. Consequently, there is a need to define poor response and to prevent or correct it by optimizing treatment regimens within accepted guidelines. Recognition of a poor response is an indication for action by the treating physician, either to modify the therapy or to review the primary diagnosis leading either to discontinuation or change of therapy. This review discusses the optimal investigation of the child who is a candidate for GH or IGF-1 therapy so that a diagnosis-based choice of therapy and dosage can be made. The relevant parameters in the evaluation of growth response are described together with the definitions of poor response. Prevention of poor response is addressed by discussion of strategy for first-year management with GH and IGF-1. Adherence to therapy is reviewed as is the recommended action following the identification of the poorly responding patient. The awareness, recognition and management of poor response to growth-promoting therapy will lead to better patient care, greater cost-effectiveness and increased opportunities for clinical benefit.

AB - Growth hormone (GH) is widely prescribed for children with short stature across a range of growth disorders. Recombinant human (rh) insulin-like growth factor-1 (rhIGF-1) therapy is approved for severe primary IGF-I deficiency - a state of severe GH resistance. Evidence is increasing for an unacceptably high rate of poor or unsatisfactory response to growth-promoting therapy (i.e. not leading to significant catch up growth) in terms of change in height standard deviation score (SDS) and height velocity (HV) in many approved indications. Consequently, there is a need to define poor response and to prevent or correct it by optimizing treatment regimens within accepted guidelines. Recognition of a poor response is an indication for action by the treating physician, either to modify the therapy or to review the primary diagnosis leading either to discontinuation or change of therapy. This review discusses the optimal investigation of the child who is a candidate for GH or IGF-1 therapy so that a diagnosis-based choice of therapy and dosage can be made. The relevant parameters in the evaluation of growth response are described together with the definitions of poor response. Prevention of poor response is addressed by discussion of strategy for first-year management with GH and IGF-1. Adherence to therapy is reviewed as is the recommended action following the identification of the poorly responding patient. The awareness, recognition and management of poor response to growth-promoting therapy will lead to better patient care, greater cost-effectiveness and increased opportunities for clinical benefit.

UR - http://www.scopus.com/inward/record.url?scp=84863649330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863649330&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2012.04420.x

DO - 10.1111/j.1365-2265.2012.04420.x

M3 - Article

VL - 77

SP - 169

EP - 181

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -